IFNG and acute myeloid leukemia: Other groups have utilized CAR-NK92 cells to redirect the CD123 antigen, tested in AML cell-line-engrafted mice or patient-derived xenotransplantation AML models, and showed in vitro efficacy and systemic secretion of inflammatory cytokines, such as IFN-γ, but only modest AML control in vivo, mainly due to relatively short NK persistence and limited organ tropism [64].